Treating castration resistant prostate cancer means that failure within the advanced therapy supply chain has a catastrophic impact on patients.
SOTIO is part of the PPF Group and leads its efforts to build a diverse biotechnology portfolio through its own research development, collaborations, in-licensing, investments, mergers and acquisitions. They are currently testing the safety and efficiency of DCVAC/PCa treatment in an extensive global multi-center Phase III clinical trial for prostate cancer immunotherapy called the VIABLE study.
For the supply chain, this means management of time critical, temperature controlled shipments to/from more than 20 EU and non-EU countries and the treatment of over 1000 patients. SOTIO had delivered early trials by using its in-house cryo-store and shipping under dry-ice to recipient centers. The plan was to scale this system into the PhIII trial. However, this proved to be impractical and too expensive due to a number of barriers.
By utilizing Fisher BioServices' CryoHubSM infrastructure and supply chain management experience, SOTIO has fully completed enrollment of the VIABLE study and treated already more than 1000 patients. Are you interested in learning how this was achieved? Download our collaborative case study on how the use of dispersed storage and cold chain logistics, around a central manufacturing facility, created a cost efficient and robust supply chain.